News
MyChesCo on MSN1h
Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia GravisHOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback